Vimarsana
Biggest News Aggregation in the World

Important Targets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Important Targets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Important Targets Today - Breaking & Trending Today

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease - Vimarsana News

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Published: June 10, 2024

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

Source: finanznachrichten.de
Related Topics:
United KingdomHong KongUnited StatesSouth KoreaSaudi ArabiaGreat BritainChuck TrianoChristophera ViehbacherLinkedinand FacebookTsujim ProtofibrilsJack CoxHaruo NaitoJulie EdelmanDrug AdministrationEuropean UnionUnited Nations Sustainable Development Goals SdgsInvestor Relations DepartmentExchange CommissionEisai Co LtdNational Institutes Of HealthCommunications DepartmentWashington University School Of MedicineEisai Europe LtdNational Institute OnAlzheimer Clinical Trial Consortium
Biogen: LEQEMBI Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea - Vimarsana News

Biogen: LEQEMBI Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea

Published: May 28, 2024

TOKYO and CAMBRIDGE, Mass., May 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble

Source: finanznachrichten.de
Related Topics:
South KoreaUnited KingdomJulie EdelmanTsujim ProtofibrilsJack CoxEisai Korea IncNational Institute Of Dementia KoreanPublic Relations DepartmentEisai Co LtdMinistry Of FoodExchange CommissionEisai IncUnited Nations Sustainable Development Goals SdgsBiogen IncEuropean UnionDrug AdministrationDrug SafetyEisai KoreaClinical Dementia Rating SumBiologics License ApplicationFast TrackCorporate ConceptUnited Nations Sustainable Development GoalsNational InstituteImportant Targets
Biogen : "LEQEMBI®" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea - Vimarsana News

Biogen : "LEQEMBI®" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea

Published: May 27, 2024

TOKYO and CAMBRIDGE, Mass., May 27, 2024 - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety in South Korea has approved humanized...

Source: marketscreener.com
Related Topics:
South KoreaUnited KingdomUnited StatesHaruo NaitoChuck TrianoChristophera ViehbacherTsujim ProtofibrilsJulie EdelmanLinkedinand FacebookJack CoxNational Institute Of Dementia KoreanExchange CommissionMinistry Of FoodEisai Co LtdUnited Nations Sustainable Development Goals SdgsInvestor Relations DepartmentEuropean UnionBiogen IncPublic Relations DepartmentEisai IncDrug AdministrationEisai Korea IncDrug SafetyClinical Dementia Rating SumBiologics License Application
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - Vimarsana News

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Published: May 15, 2024

TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application to the...

Source: marketscreener.com
Related Topics:
South KoreaUnited KingdomUnited StatesSaudi ArabiaHong KongGreat BritainChuck TrianoHaruo NaitoJack CoxJulie EdelmanTsujim ProtofibrilsEisai IncWashington University School Of MedicineNational Institute OnDrug AdministrationNational Institutes Of HealthEuropean UnionEisai Co LtdUnited Nations Sustainable Development Goals SdgsAlzheimer Network Trials UnitBiogen IncExchange CommissionInvestor Relations DepartmentPrnewswire Eisai Co LtdPublic Relations Department
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA - Vimarsana News

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Published: April 1, 2024

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesUnited KingdomSaudi ArabiaSouth KoreaGreat BritainLibby HolmanJack CoxChuck TrianoChristophera ViehbacherHaruo NaitoTsujim ProtofibrilsEisai IncPrnewswire Eisai Co LtdExchange CommissionEisai Co LtdEuropean UnionEisai Europe LtdDrug AdministrationBiogen IncUnited Nations Sustainable Development Goals SdgsPublic Relations DepartmentCommunications DepartmentInvestor Relations DepartmentSupplemental Biologics License Application